

975 CHARACTERIZATION OF SIGNALING AND METABOLIC DIFFERENCES BETWEEN $\gamma\delta$ AND $\alpha\beta$ CAR T CELLS

Xiomar Bustos*, Daniel Abate-Daga, Leticia Tordesillas. *H. Lee Moffitt Cancer Center & Research, Tampa, FL, United States*

of Laboratory Animals manual published by the National Institutes of Health.

<http://dx.doi.org/10.1136/jitc-2022-SITC2022.0975>

Background $\gamma\delta$ T cell-based immunotherapies have emerged as an alternative to the traditional $\alpha\beta$ T cell-based products. For example, our group has shown that $\gamma\delta$ CAR T cells can reduce tumor burden and mitigate tumor-induced bone deterioration in a preclinical model of bone metastatic prostate cancer. In the present study, we investigated the signaling events triggered by a second-generation CAR (originally designed for $\alpha\beta$ T cells) in $\gamma\delta$ T cells, to test the hypothesis that CAR-induced signaling varies depending on the T cell subset. The ultimate goal of our study is to gain mechanistic insight into the biology of $\gamma\delta$ T cells and to inform future CAR design for improved $\gamma\delta$ -based adoptive cell therapies.

Methods We designed our analysis as a side-by-side comparison of phosphorylation events, resulting from CAR activation, between $\gamma\delta$ and $\alpha\beta$ T cells. These were expanded in parallel from a healthy donor and transduced with a retroviral vector (MSGV1) to express a second-generation anti-PSCA CAR (PSCA-8t28z). CAR-T cells were then cocultured independently with metabolically labelled C4-2B-PSCA tumor cells, for 1 hour, and protein phosphorylation was quantified using Liquid Chromatography–Tandem Mass Spectrometry (LC/MS-MS). Statistically significant differences in phosphorylation were defined using a Welch's *t*-test (fold-change ≥ 1.5 and *p*-value < 0.05). Using Qiagen's Ingenuity Pathway Analysis software, we identified canonical pathways that were significantly over-represented in the population of proteins that displayed differential phosphorylation in $\gamma\delta$ CAR T cells relative to $\alpha\beta$. We used the SeaHorse XF kits for Glycolytic Rate Assay and T Cell Metabolic Profiling for functional characterization of the metabolic properties of CAR-T cells. Finally, flow cytometry was used to analyze Glut-1 expression (anti-Glut1, clone 202915), glucose intake (2NBDG), mitochondrial mass (Mito-Tracker Green), and mitochondrial membrane polarization (TMRE).

Results We identified 323 phosphorylation events that were differentially abundant between T cell subsets. Within this group, glycolysis and gluconeogenesis were within the top overrepresented canonical pathways. Stimulated $\gamma\delta$ T cells showed significantly lower glycolytic rate compared to $\alpha\beta$. CAR expression was accompanied by higher glycolytic rate and expression of Glut-1 receptor in both T-cell types. Finally, oxidative phosphorylation (OXPHOS) was lower in $\gamma\delta$ CAR T cells, potentially related to their also lower mitochondrial mass.

Conclusions CAR-induced signaling varies among T cell subsets, and $\gamma\delta$ T cells display lower glycolytic and OXPHOS rates upon activation. Ongoing efforts are focused on delineating molecular causes and functional consequences of the metabolic differences between $\alpha\beta$ and $\gamma\delta$ T cells.

Acknowledgements This work has been supported in part by the Bioinformatics, the Proteomics, and the Flow Cytometry Core Facilities at the Moffitt Cancer Center, an NCI designated Comprehensive Cancer Center (P30-CA076292). We would also like to thank Dr. Paulo Rodriguez, and Dr. Gina DeNicola for their input in the analysis of the results.

Ethics Approval All animal experiments were performed under University of South Florida IACUC approval (R1762; R7429) and in accordance with the Guidelines for the Care and Use